NORDIC: Nitric Oxide-Derived Oxidants and Regional Endothelial and Diastolic Dysfunction in Dilated Cardiomyopathy

Exclusion Criteria

• •1. Known or confirmed newly-diagnosed diabetes mellitus (2004 ADA criteria)
• •2. Major cardiovascular event (myocardial infarction, unstable angina, stroke, transient ischemic attack, pulmonary embolism), or major surgery \<1 month of enrollment
• •3. Hospitalization or emergency room visits for heart failure exacerbation, or use of inotropic agents \< 1 month
• •4. NYHA class III or IV
• •5. Current treatment with thiazolidinediones
• •6. Allergy to rosiglitazone, or liver insufficiency (ALT \> 2.5x upper limits of normal)
• •7. Heart failure due to congenital heart disease, primary valvular disease, hypertrophic cardiomyopathy, or heart failure caused by known cardiotoxic agents (e.g. adriamycin)
• •8. End-stage renal failure on renal replacement therapy (dialysis)
• •9. Life expectancy, or expected cardiac transplantation within 12 months of enrollment
• •10. Women who are pregnant, or who are planning on becoming pregnant or are lactating. Women of childbearing potential must have a negative serum pregnancy test within 48 hours prior to the time of randomization and must use contraceptive agents
• •11. Unable or unwilling to consent to all components of the protocol. Patients unwilling to undergo 6-month follow-up should not be enrolled.